StockNews.AI
CLSD
StockNews.AI
160 days

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

1. CLSD to report Q4 and full year 2024 results on March 27, 2025. 2. Management will discuss results on a post-earnings conference call. 3. Lead program CLS-AX for wet AMD is advancing to Phase 3 trials. 4. XIPERE® is commercially available in the U.S. through partners. 5. CLSD's SCS® Microinjector offers a novel delivery method for eye therapies.

Earnings
-3.63%Current Return
VS
-1.02%S&P 500
$0.851903/12 07:07 AM EDTEvent Start
$0.82103/13 01:43 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report could show positive advancements in drug development, impacting investor sentiment. Previous earnings reports with good news often led to stock price increases.

How important is it?

The article provides critical updates on financial results and drug progression, directly impacting investor expectations and stock valuation.

Why Short Term?

The immediate impact will be felt around the upcoming earnings release, important for short-term investors. Long-term impacts depend on sustained performance and clinical results.

Related Companies

XBIOOPHTREGN
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and entering conference code: 733956. The Company suggests participants join 15 minutes in advance of the event. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X. Source: Clearside Biomedical, Inc.

Related News